Neurodegenerative Diseases News and Research

RSS

New drug candidate reduces toxic protein clumps of Huntington's disease

An experimental drug has been shown to alleviate symptoms of Huntington's disease and extend lifespan in mouse models. Further studies are required to determine whether these results may also apply to humans.

29 Jun 2026

Iron overload gradually increases neurons' vulnerability to neurodegeneration

Neurodegenerative diseases affect tens of millions of people worldwide. Among these, Alzheimer's and Parkinson's diseases are the most common; in the United States alone, the Alzheimer's Disease Association and Parkinson's Foundation report roughly 7 million people with Alzheimer's and another million with Parkinson's.

25 Jun 2026

New review highlights TREM-1 receptor as target for inflammatory diseases

A comprehensive review recently published in Current Molecular Pharmacology consolidates the growing evidence surrounding the Triggering Receptor Expressed on Myeloid Cells-1 (TREM-1) as a central amplifier of innate immune responses and a promising therapeutic target for a range of inflammatory diseases.

25 Jun 2026

Discovery of karyoptosis opens new therapeutic targets for Alzheimer's and frontotemporal dementia

Markers of a new mechanism for cell death, called karyoptosis, have been found in brains of patients with Alzheimer's disease and frontotemporal dementia (FTD).

25 Jun 2026

Blueberries may boost children's memory and mood

Research suggests blueberry compounds could enhance mood and cognitive function in children, yet stronger evidence is required for clinical recommendations.

25 Jun 2026

Zebrafish model unlocks new insights into hereditary brain disease

CADASIL, an inherited disease caused by mutations in the NOTCH3 gene, damages the brain’s small blood vessels, leading to strokes, cognitive decline, and early dementia.

24 Jun 2026

Pioneering technique maps the proteome of individual cardiomyocytes

Two research teams at the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) have developed a pioneering technique in Spain to characterize the proteome of individual cardiomyocytes-the cells responsible for heart contraction.

24 Jun 2026

Study finds no detectable short-term brain harm after one youth soccer season

A prospective European cohort study found that one season of competitive youth soccer was not associated with detectable short-term differences in cognition, behavior, balance, MRI measures, or blood biomarkers compared with noncontact sports. However, soccer players had higher preseason tNAA, GFAP, and NfL levels than controls, highlighting the need for larger, multiyear studies to clarify whether repeated heading has cumulative effects.

23 Jun 2026

TRIMTECH Therapeutics brings total seed round to $47 M with additional investment of $14 M to further develop TRIMTAC and TRIMGLUE targeted protein degradation portfolio

TRIMTECH Therapeutics, a biotechnology company developing novel small molecule therapies that target and degrade protein aggregates associated with neurodegenerative diseases, today announced it has raised an additional $14 million in seed funding, bringing the total for the round to $47 million (£35 million).

From TRIMTECH Therapeutics 23 Jun 2026

AI discovers hidden antibiotic candidates inside disease-causing prions

New antibiotic candidates for drug-resistant bacteria may reside inside prions, mis-folded protein in the brain best known for rare and fatal degenerative brain diseases.

19 Jun 2026

Developing brain cells routinely repair severe DNA damage during migration

Newborn nerve cells must squeeze through crowded, narrow spaces-through dense tissue, past other cells, between fibers-to reach the areas where they form neural circuits in the brain cortex.

17 Jun 2026

Study reveals different factors driving rising neurological disease rates

The growing number of people living with Parkinson's disease (PD), multiple sclerosis (MS) and motor neuron disease (MND) is being driven by different underlying factors, according to new research due to be presented at the European Academy of Neurology (EAN) Congress 2026 and published in Neurology.

15 Jun 2026

New peptide strategy may protect brain cells involved in Parkinson's disease

Researchers at the Federal University of São Paulo (UNIFESP) in Brazil have discovered a new strategy that may protect neurons and other brain cells involved in Parkinson's disease in the future.

12 Jun 2026

Biotechnology breakthrough could revolutionize treatment for neurodegenerative diseases

A research team from the School of Biomedical Sciences at the LKS Faculty of Medicine, the University of Hong Kong (HKUMed), has achieved a significant breakthrough in biotechnology that could revolutionize treatment strategies for neurodegenerative diseases.

12 Jun 2026

The cerebellum may help aging brains stay sharper

A large MRI study of more than 47,000 adults found that cerebellar aging is uneven, with posterior association regions and some motor-related areas showing steeper age-related changes. Larger cerebellar volumes were linked to better cognitive performance, supporting a threshold-reserve model in which the cerebellum may help sustain cognition before Alzheimer’s pathology becomes widespread.

11 Jun 2026

Review uses evolutionary lens to examine modern human aging rates

A review article now published in "Nature Reviews Genetics" brings together evolutionary theory, comparative genomics and large-scale human genetics to explain why we age and why aging rates differ among individuals and species.

11 Jun 2026

Scientists reveal how cGAS-STING fuels brain inflammation and neurodegeneration

The cGAS-STING pathway is emerging as a key driver of chronic neuroinflammation through its effects on glial activation, neuronal stress, blood-brain barrier integrity, and type I interferon signaling. The review highlights why selective, context-dependent modulation of cGAS-STING could help treat neurodegenerative diseases, while preserving its essential roles in antiviral defense and tumor surveillance.

10 Jun 2026

Grant fuels research into SYNGAP1-linked behavioral abnormalities

CURE SYNGAP1 501(c)(3) is pleased to announce a $130,000 grant to Dr. Helen Willsey and Dr. David Kastner at the University of California, San Francisco (UCSF).

5 Jun 2026

Antibody fragment offers safer alternative for Alzheimer disease treatment

In 2025, the European Medicines Agency approved two antibodies for Alzheimer's disease: lecanemab (Leqembi, from Biogen) and donanemab (KisunlaTM, from Eli Lilly and Company), both based on immunotherapy (the use of molecules from the immune system to treat diseases).

5 Jun 2026

Strength training and cardio combo work best together

Research shows that combining resistance training with aerobic exercise significantly reduces mortality risk, emphasizing the importance of physical activity.

5 Jun 2026